Koers Acasti Pharma Inc Toronto S.E.
Aandelen
APO
CA00430K1057
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- CAD | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 41,24 mln. 29,95 mln. 27,75 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -18 mln. -13,07 mln. -12,11 mln. | Nettowinst (verlies) 2025 * | -23 mln. -16,7 mln. -15,47 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,18
x | K/w-verhouding 2025 * |
-2,8
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 83,98% |
Recentste transcriptie over Acasti Pharma Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Prashant Kohli
CEO | Chief Executive Officer | 52 | 01-08-21 |
Director of Finance/CFO | 52 | 05/01 | |
Carrie D'Andrea
CTO | Chief Tech/Sci/R&D Officer | 52 | 08-05-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
A. Davis
BRD | Director/Board Member | 57 | 10-10-23 |
Director/Board Member | - | 10-10-23 | |
Santosh Kottayil
BRD | Director/Board Member | - | 10-10-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+45,82% | 754 mld. | |
+40,95% | 630 mld. | |
-6,16% | 352 mld. | |
+19,86% | 331 mld. | |
+9,32% | 298 mld. | |
+18,45% | 250 mld. | |
+11,88% | 217 mld. | |
-0,78% | 216 mld. | |
+5,90% | 164 mld. |
- Beurs
- Aandelen
- Koers ACST
- Koers APO